HomeCompareESALF vs YUM

ESALF vs YUM: Dividend Comparison 2026

ESALF yields 3.60% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $81.6K in total portfolio value· pulled ahead in Year 3
10 years
ESALF
ESALF
● Live price
3.60%
Share price
$30.00
Annual div
$1.08
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$474.23
Full ESALF calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — ESALF vs YUM

📍 YUM pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALFYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALF + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALF pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALF
Annual income on $10K today (after 15% tax)
$306.00/yr
After 10yr DRIP, annual income (after tax)
$403.10/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, YUM beats the other by $33,560.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALF + YUM for your $10,000?

ESALF: 50%YUM: 50%
100% YUM50/50100% ESALF
Portfolio after 10yr
$66.2K
Annual income
$20,215.77/yr
Blended yield
30.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ESALF
No analyst data
Altman Z
2.9
Piotroski
7/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALF buys
0
YUM buys
0
No recent congressional trades found for ESALF or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALFYUM
Forward yield3.60%1.85%
Annual dividend / share$1.08$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%51.4%
Portfolio after 10y$25.4K$107.0K
Annual income after 10y$474.23$39,957.33
Total dividends collected$4.2K$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: ESALF vs YUM ($10,000, DRIP)

YearESALF PortfolioESALF Income/yrYUM PortfolioYUM Income/yrGap
1$11,061$361.44$10,980$280.44+$81.00ESALF
2$12,211$375.14$12,185$435.72+$26.00ESALF
3← crossover$13,454$388.58$13,722$684.14$268.00YUM
4$14,798$401.74$15,773$1,090.14$975.00YUM
5$16,248$414.60$18,650$1,773.02$2.4KYUM
6$17,813$427.16$22,921$2,966.37$5.1KYUM
7$19,499$439.41$29,685$5,158.69$10.2KYUM
8$21,315$451.34$41,216$9,453.02$19.9KYUM
9$23,270$462.94$62,672$18,571.31$39.4KYUM
10$25,373$474.23$107,016$39,957.33$81.6KYUM

ESALF vs YUM: Complete Analysis 2026

ESALFStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALF Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ESALF vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALF vs SCHDESALF vs JEPIESALF vs OESALF vs KOESALF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.